Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group
Philadelphia chromosome-like (Ph-like) acute lymphoblastic leukemia (ALL) is a high-risk subtype characterized by genomic alterations that activate cytokine receptor and kinase signaling. We examined the frequency and spectrum of targetable genetic lesions in a retrospective cohort of 1389 consecuti...
Gespeichert in:
| Veröffentlicht in: | Blood Jg. 129; H. 25; S. 3352 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
22.06.2017
|
| Schlagworte: | |
| ISSN: | 1528-0020, 1528-0020 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Philadelphia chromosome-like (Ph-like) acute lymphoblastic leukemia (ALL) is a high-risk subtype characterized by genomic alterations that activate cytokine receptor and kinase signaling. We examined the frequency and spectrum of targetable genetic lesions in a retrospective cohort of 1389 consecutively diagnosed patients with childhood B-lineage ALL with high-risk clinical features and/or elevated minimal residual disease at the end of remission induction therapy. The Ph-like gene expression profile was identified in 341 of 1389 patients, 57 of whom were excluded from additional analyses because of the presence of
-
(n = 46) or
-
(n = 11). Among the remaining 284 patients (20.4%), overexpression and rearrangement of
(
-
or
-
) were identified in 124 (43.7%), with concomitant genomic alterations activating the JAK-STAT pathway (
,
,
) identified in 63 patients (50.8% of those with
rearrangement). Among the remaining patients, using reverse transcriptase polymerase chain reaction or transcriptome sequencing, we identified targetable ABL-class fusions (
,
,
, and
) in 14.1%,
rearrangements or
fusions in 8.8%, alterations activating other JAK-STAT signaling genes (
,
,
) in 6.3% or other kinases (
,
,
) in 4.6%, and mutations involving the Ras pathway (
,
,
,
) in 6% of those with Ph-like ALL. We identified 8 new rearrangement partners for 4 kinase genes previously reported to be rearranged in Ph-like ALL. The current findings provide support for the precision-medicine testing and treatment approach for Ph-like ALL implemented in Children's Oncology Group ALL trials. |
|---|---|
| AbstractList | Philadelphia chromosome-like (Ph-like) acute lymphoblastic leukemia (ALL) is a high-risk subtype characterized by genomic alterations that activate cytokine receptor and kinase signaling. We examined the frequency and spectrum of targetable genetic lesions in a retrospective cohort of 1389 consecutively diagnosed patients with childhood B-lineage ALL with high-risk clinical features and/or elevated minimal residual disease at the end of remission induction therapy. The Ph-like gene expression profile was identified in 341 of 1389 patients, 57 of whom were excluded from additional analyses because of the presence of
-
(n = 46) or
-
(n = 11). Among the remaining 284 patients (20.4%), overexpression and rearrangement of
(
-
or
-
) were identified in 124 (43.7%), with concomitant genomic alterations activating the JAK-STAT pathway (
,
,
) identified in 63 patients (50.8% of those with
rearrangement). Among the remaining patients, using reverse transcriptase polymerase chain reaction or transcriptome sequencing, we identified targetable ABL-class fusions (
,
,
, and
) in 14.1%,
rearrangements or
fusions in 8.8%, alterations activating other JAK-STAT signaling genes (
,
,
) in 6.3% or other kinases (
,
,
) in 4.6%, and mutations involving the Ras pathway (
,
,
,
) in 6% of those with Ph-like ALL. We identified 8 new rearrangement partners for 4 kinase genes previously reported to be rearranged in Ph-like ALL. The current findings provide support for the precision-medicine testing and treatment approach for Ph-like ALL implemented in Children's Oncology Group ALL trials. Philadelphia chromosome-like (Ph-like) acute lymphoblastic leukemia (ALL) is a high-risk subtype characterized by genomic alterations that activate cytokine receptor and kinase signaling. We examined the frequency and spectrum of targetable genetic lesions in a retrospective cohort of 1389 consecutively diagnosed patients with childhood B-lineage ALL with high-risk clinical features and/or elevated minimal residual disease at the end of remission induction therapy. The Ph-like gene expression profile was identified in 341 of 1389 patients, 57 of whom were excluded from additional analyses because of the presence of BCR-ABL1 (n = 46) or ETV6-RUNX1 (n = 11). Among the remaining 284 patients (20.4%), overexpression and rearrangement of CRLF2 (IGH-CRLF2 or P2RY8-CRLF2) were identified in 124 (43.7%), with concomitant genomic alterations activating the JAK-STAT pathway (JAK1, JAK2, IL7R) identified in 63 patients (50.8% of those with CRLF2 rearrangement). Among the remaining patients, using reverse transcriptase polymerase chain reaction or transcriptome sequencing, we identified targetable ABL-class fusions (ABL1, ABL2, CSF1R, and PDGFRB) in 14.1%, EPOR rearrangements or JAK2 fusions in 8.8%, alterations activating other JAK-STAT signaling genes (IL7R, SH2B3, JAK1) in 6.3% or other kinases (FLT3, NTRK3, LYN) in 4.6%, and mutations involving the Ras pathway (KRAS, NRAS, NF1, PTPN11) in 6% of those with Ph-like ALL. We identified 8 new rearrangement partners for 4 kinase genes previously reported to be rearranged in Ph-like ALL. The current findings provide support for the precision-medicine testing and treatment approach for Ph-like ALL implemented in Children's Oncology Group ALL trials.Philadelphia chromosome-like (Ph-like) acute lymphoblastic leukemia (ALL) is a high-risk subtype characterized by genomic alterations that activate cytokine receptor and kinase signaling. We examined the frequency and spectrum of targetable genetic lesions in a retrospective cohort of 1389 consecutively diagnosed patients with childhood B-lineage ALL with high-risk clinical features and/or elevated minimal residual disease at the end of remission induction therapy. The Ph-like gene expression profile was identified in 341 of 1389 patients, 57 of whom were excluded from additional analyses because of the presence of BCR-ABL1 (n = 46) or ETV6-RUNX1 (n = 11). Among the remaining 284 patients (20.4%), overexpression and rearrangement of CRLF2 (IGH-CRLF2 or P2RY8-CRLF2) were identified in 124 (43.7%), with concomitant genomic alterations activating the JAK-STAT pathway (JAK1, JAK2, IL7R) identified in 63 patients (50.8% of those with CRLF2 rearrangement). Among the remaining patients, using reverse transcriptase polymerase chain reaction or transcriptome sequencing, we identified targetable ABL-class fusions (ABL1, ABL2, CSF1R, and PDGFRB) in 14.1%, EPOR rearrangements or JAK2 fusions in 8.8%, alterations activating other JAK-STAT signaling genes (IL7R, SH2B3, JAK1) in 6.3% or other kinases (FLT3, NTRK3, LYN) in 4.6%, and mutations involving the Ras pathway (KRAS, NRAS, NF1, PTPN11) in 6% of those with Ph-like ALL. We identified 8 new rearrangement partners for 4 kinase genes previously reported to be rearranged in Ph-like ALL. The current findings provide support for the precision-medicine testing and treatment approach for Ph-like ALL implemented in Children's Oncology Group ALL trials. |
| Author | Roberts, Kathryn G Jenkins, Heather Stonerock, Eileen Devidas, Meenakshi Shao, Ying Dai, Yunfeng Salzer, Wanda L Heerema, Nyla A Willman, Cheryl L Gastier-Foster, Julie M Easton, John Burke, Michael J Zhang, Jinghui Angiolillo, Anne L Tran, Thai Hoa Nguyen, Jonathan V Zweidler-McKay, Patrick A Reshmi, Shalini C Carroll, William L Harvey, Richard C Smith, Amy Valentine, Marc Liu, Yu Gu, Zhaohui Payne-Turner, Debbie Chen, I-Ming Raetz, Elizabeth A Rabin, Karen R Li, Yongjin Wood, Brent L Loh, Mignon L Hunger, Stephen P Carroll, 3rd, Andrew J Borowitz, Michael J Mullighan, Charles G |
| Author_xml | – sequence: 1 givenname: Shalini C surname: Reshmi fullname: Reshmi, Shalini C organization: Department of Pathology, The Ohio State University College of Medicine, Columbus, OH – sequence: 2 givenname: Richard C orcidid: 0000-0002-4904-9767 surname: Harvey fullname: Harvey, Richard C organization: University of New Mexico Cancer Center, Albuquerque, NM – sequence: 3 givenname: Kathryn G surname: Roberts fullname: Roberts, Kathryn G organization: Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN – sequence: 4 givenname: Eileen surname: Stonerock fullname: Stonerock, Eileen organization: Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, OH – sequence: 5 givenname: Amy surname: Smith fullname: Smith, Amy organization: Comprehensive Cancer Center, The Ohio State University College of Medicine, Columbus, OH – sequence: 6 givenname: Heather surname: Jenkins fullname: Jenkins, Heather organization: Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, OH – sequence: 7 givenname: I-Ming surname: Chen fullname: Chen, I-Ming organization: University of New Mexico Cancer Center, Albuquerque, NM – sequence: 8 givenname: Marc surname: Valentine fullname: Valentine, Marc organization: Department of Cytogenetics and – sequence: 9 givenname: Yu surname: Liu fullname: Liu, Yu organization: Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN – sequence: 10 givenname: Yongjin surname: Li fullname: Li, Yongjin organization: Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN – sequence: 11 givenname: Ying surname: Shao fullname: Shao, Ying organization: Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN – sequence: 12 givenname: John surname: Easton fullname: Easton, John organization: Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN – sequence: 13 givenname: Debbie surname: Payne-Turner fullname: Payne-Turner, Debbie organization: Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN – sequence: 14 givenname: Zhaohui surname: Gu fullname: Gu, Zhaohui organization: Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN – sequence: 15 givenname: Thai Hoa surname: Tran fullname: Tran, Thai Hoa organization: Department of Pediatrics, UCSF Benioff Children's Hospital and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA – sequence: 16 givenname: Jonathan V surname: Nguyen fullname: Nguyen, Jonathan V organization: Department of Pediatrics, UCSF Benioff Children's Hospital and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA – sequence: 17 givenname: Meenakshi surname: Devidas fullname: Devidas, Meenakshi organization: Department of Biostatistics, University of Florida, Gainesville, FL – sequence: 18 givenname: Yunfeng surname: Dai fullname: Dai, Yunfeng organization: Department of Biostatistics, University of Florida, Gainesville, FL – sequence: 19 givenname: Nyla A surname: Heerema fullname: Heerema, Nyla A organization: Department of Pathology, The Ohio State University College of Medicine, Columbus, OH – sequence: 20 givenname: Andrew J surname: Carroll, 3rd fullname: Carroll, 3rd, Andrew J organization: Department of Genetics, University of Alabama at Birmingham, Birmingham, AL – sequence: 21 givenname: Elizabeth A surname: Raetz fullname: Raetz, Elizabeth A organization: Department of Pediatrics, University of Utah, Salt Lake City, UT – sequence: 22 givenname: Michael J surname: Borowitz fullname: Borowitz, Michael J organization: Department of Pathology, Johns Hopkins University, Baltimore, MD – sequence: 23 givenname: Brent L surname: Wood fullname: Wood, Brent L organization: Seattle Children's Hospital, Seattle, WA – sequence: 24 givenname: Anne L surname: Angiolillo fullname: Angiolillo, Anne L organization: Children's National Medical Center, Washington, DC – sequence: 25 givenname: Michael J surname: Burke fullname: Burke, Michael J organization: Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI – sequence: 26 givenname: Wanda L surname: Salzer fullname: Salzer, Wanda L organization: US Army Medical Research and Materiel Command, Fort Detrick, MD – sequence: 27 givenname: Patrick A surname: Zweidler-McKay fullname: Zweidler-McKay, Patrick A organization: Department of Pediatrics, MD Anderson Cancer Center, Houston, TX – sequence: 28 givenname: Karen R surname: Rabin fullname: Rabin, Karen R organization: Department of Pediatrics, Baylor College of Medicine, Houston, TX – sequence: 29 givenname: William L surname: Carroll fullname: Carroll, William L organization: Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY – sequence: 30 givenname: Jinghui surname: Zhang fullname: Zhang, Jinghui organization: Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN – sequence: 31 givenname: Mignon L surname: Loh fullname: Loh, Mignon L organization: Department of Pediatrics, UCSF Benioff Children's Hospital and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA – sequence: 32 givenname: Charles G surname: Mullighan fullname: Mullighan, Charles G organization: Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN – sequence: 33 givenname: Cheryl L surname: Willman fullname: Willman, Cheryl L organization: University of New Mexico Cancer Center, Albuquerque, NM – sequence: 34 givenname: Julie M surname: Gastier-Foster fullname: Gastier-Foster, Julie M organization: Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH; and – sequence: 35 givenname: Stephen P surname: Hunger fullname: Hunger, Stephen P organization: Department of Pediatrics, Children's Hospital of Philadelphia and Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28408464$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkLtOwzAARS1URB_wBwh5g8XgV2KbrVRQkCJ1KSOK7MRJTFO72MnQvweJIjGdOxzd4czBxAdvAbgm-J4QSR9MH0KNKCY5IhSJTCqhzsCMZFQijCme_NtTME_pE2PCGc0uwJRKjiXP-Qx8bHVs7aBNb-HOeZ0sbK23sBmTCz5B52Hn2g5Fl3bwCS2L4hFqmIaxPsImhj0cOgtXnevraP1tghtfhT60R7iOYTxcgvNG98lenbgA7y_P29UrKjbrt9WyQFVG1YAUs0xwSoQStaLGVFISmeUESypxYwTLmGZGYmYwbwzRVV6JSmmpDTNEEkUX4O739xDD12jTUO5dqmzfa2_DmEoipcyF4Dz7UW9O6mj2ti4P0e11PJZ_Seg3sVpkuw |
| CitedBy_id | crossref_primary_10_1038_s41408_020_0308_3 crossref_primary_10_1002_gcc_22901 crossref_primary_10_1200_EDBK_278171 crossref_primary_10_3389_fcell_2022_712484 crossref_primary_10_1016_j_cancergen_2020_03_001 crossref_primary_10_1002_ajh_26487 crossref_primary_10_1080_10428194_2023_2197538 crossref_primary_10_1097_HS9_0000000000000053 crossref_primary_10_1016_j_leukres_2022_106925 crossref_primary_10_3390_ijms22126411 crossref_primary_10_1016_j_beha_2017_06_001 crossref_primary_10_1038_s41598_025_10262_0 crossref_primary_10_1182_blood_2018_10_881961 crossref_primary_10_1007_s11899_018_0457_7 crossref_primary_10_1016_j_cancergen_2024_03_005 crossref_primary_10_1182_bloodadvances_2021006076 crossref_primary_10_1038_s41417_022_00511_z crossref_primary_10_3389_fonc_2023_1322403 crossref_primary_10_1177_2040620720903531 crossref_primary_10_1111_bjh_16616 crossref_primary_10_1182_bloodadvances_2018016584 crossref_primary_10_1080_14728214_2021_1956462 crossref_primary_10_1016_j_beha_2019_101095 crossref_primary_10_1016_j_beha_2019_101096 crossref_primary_10_1002_cam4_3099 crossref_primary_10_1016_j_labinv_2025_104201 crossref_primary_10_1002_jcp_26539 crossref_primary_10_1002_ajh_26908 crossref_primary_10_3390_ijms23063067 crossref_primary_10_1182_blood_2017_09_804070 crossref_primary_10_1016_j_exphem_2018_07_007 crossref_primary_10_1182_blood_2017_11_817510 crossref_primary_10_3390_ijms23052755 crossref_primary_10_1038_s41388_023_02705_7 crossref_primary_10_3390_cancers12123498 crossref_primary_10_1016_j_clml_2021_12_006 crossref_primary_10_1111_ijlh_14415 crossref_primary_10_1182_bloodadvances_2021005634 crossref_primary_10_1002_ajh_25126 crossref_primary_10_1007_s11899_018_0456_8 crossref_primary_10_1016_S2352_3026_20_30362_8 crossref_primary_10_1038_s41409_025_02693_0 crossref_primary_10_1186_s13039_023_00645_1 crossref_primary_10_1200_JCO_18_00573 crossref_primary_10_1007_s40291_025_00775_9 crossref_primary_10_1186_s40478_018_0551_z crossref_primary_10_5858_arpa_2019_0194_RA crossref_primary_10_1002_hon_2541 crossref_primary_10_3390_cancers10040110 crossref_primary_10_1182_blood_2020010144 crossref_primary_10_1002_mgg3_1110 crossref_primary_10_1002_pbc_30996 crossref_primary_10_1182_blood_2018_04_841676 crossref_primary_10_1016_j_clml_2020_08_011 crossref_primary_10_1016_j_bneo_2025_100109 crossref_primary_10_1016_j_leukres_2021_106683 crossref_primary_10_1159_000490121 crossref_primary_10_1038_s41416_023_02511_8 crossref_primary_10_1016_j_lrr_2025_100530 crossref_primary_10_1093_ajcp_aqz093 crossref_primary_10_1016_j_yamp_2019_07_004 crossref_primary_10_1016_j_cancergen_2020_01_051 crossref_primary_10_1200_EDBK_349647 crossref_primary_10_1007_s11033_022_07337_w crossref_primary_10_1038_s41375_019_0412_1 crossref_primary_10_1038_s41416_023_02294_y crossref_primary_10_1097_MPH_0000000000001771 crossref_primary_10_1182_blood_2018_04_784157 crossref_primary_10_3390_cancers16233965 crossref_primary_10_1080_14737140_2017_1347507 crossref_primary_10_1182_blood_2022015853 crossref_primary_10_1182_blood_2024026482 crossref_primary_10_1186_s13073_024_01324_5 crossref_primary_10_1038_s41375_024_02421_5 crossref_primary_10_1093_clinchem_hvaa221 crossref_primary_10_1016_j_jmoldx_2019_05_006 crossref_primary_10_3390_lymphatics1020011 crossref_primary_10_1053_j_semdp_2023_04_003 crossref_primary_10_1016_j_bbmt_2018_09_041 crossref_primary_10_1182_bloodadvances_2024014354 crossref_primary_10_1371_journal_pone_0221509 crossref_primary_10_1053_j_seminhematol_2018_05_001 crossref_primary_10_1016_S2352_3026_20_30353_7 crossref_primary_10_3389_fped_2017_00263 crossref_primary_10_1007_s10238_023_01131_z crossref_primary_10_1182_bloodadvances_2017014704 crossref_primary_10_1038_s41598_021_91760_9 crossref_primary_10_1053_j_semdp_2023_10_001 crossref_primary_10_1080_17474086_2018_1509702 crossref_primary_10_1182_blood_2020008536 crossref_primary_10_12688_f1000research_16074_1 crossref_primary_10_1002_cncr_31848 crossref_primary_10_1007_s12288_018_0997_y crossref_primary_10_3389_fonc_2024_1498409 crossref_primary_10_1182_bloodadvances_2020001890 crossref_primary_10_1016_j_mayocp_2019_04_030 crossref_primary_10_1002_gcc_22745 crossref_primary_10_1111_joim_13508 crossref_primary_10_1111_ijlh_13012 crossref_primary_10_1038_s41375_022_01620_2 crossref_primary_10_1016_j_critrevonc_2019_07_016 crossref_primary_10_1016_j_semcancer_2021_09_013 crossref_primary_10_7759_cureus_90563 crossref_primary_10_1182_blood_2017_12_821363 crossref_primary_10_1111_bjh_20057 crossref_primary_10_1186_s13039_023_00652_2 crossref_primary_10_1016_j_bbcan_2021_188571 crossref_primary_10_1016_j_canlet_2021_04_027 crossref_primary_10_1007_s12185_018_2474_7 crossref_primary_10_1080_10428194_2019_1658105 crossref_primary_10_1038_s41409_021_01253_6 crossref_primary_10_1016_j_jmoldx_2022_08_001 crossref_primary_10_1038_s41375_021_01460_6 crossref_primary_10_1182_blood_2017_06_743252 crossref_primary_10_1038_s41379_018_0165_9 crossref_primary_10_1111_petr_14024 crossref_primary_10_1038_s41375_022_01799_4 crossref_primary_10_1111_bjh_15251 crossref_primary_10_1002_cnr2_1587 crossref_primary_10_1038_s41375_020_01091_3 crossref_primary_10_1002_cnr2_1901 crossref_primary_10_3389_fimmu_2025_1627235 crossref_primary_10_1002_acg2_69 crossref_primary_10_1016_j_biopha_2019_108913 crossref_primary_10_1093_ajcp_aqaa038 crossref_primary_10_3389_fonc_2020_00359 crossref_primary_10_1007_s00277_023_05236_z crossref_primary_10_1007_s00761_024_01669_x crossref_primary_10_1007_s12288_025_01968_2 crossref_primary_10_1080_0284186X_2021_1900908 crossref_primary_10_3390_medicina58101386 crossref_primary_10_1634_theoncologist_2018_0272 crossref_primary_10_1016_j_yamp_2025_05_002 crossref_primary_10_1182_blood_2021011106 crossref_primary_10_1182_bloodadvances_2019000163 crossref_primary_10_1016_j_ejcped_2025_100304 crossref_primary_10_3390_jcm10173792 crossref_primary_10_5858_arpa_2022_0042_CP crossref_primary_10_1093_gigascience_giy062 crossref_primary_10_1007_s12288_024_01818_7 crossref_primary_10_1007_s00428_022_03448_8 crossref_primary_10_3389_fcell_2022_942053 crossref_primary_10_1038_s41467_022_28218_7 crossref_primary_10_1182_blood_2017_05_780015 crossref_primary_10_3390_ijms23179587 crossref_primary_10_1016_j_beha_2017_07_003 crossref_primary_10_1002_gcc_22852 crossref_primary_10_5858_arpa_2024_0082_OA crossref_primary_10_1038_s41598_021_00950_y crossref_primary_10_1016_j_clml_2022_03_007 crossref_primary_10_1016_j_modpat_2025_100741 crossref_primary_10_32725_jab_2024_024 crossref_primary_10_1182_bloodadvances_2019001008 crossref_primary_10_3390_ijms22189827 crossref_primary_10_1038_s41467_021_27197_5 crossref_primary_10_1016_j_leukres_2018_01_012 crossref_primary_10_1111_ijlh_14370 crossref_primary_10_1016_j_humpath_2023_03_002 crossref_primary_10_1080_10428194_2021_1999439 crossref_primary_10_1097_MPH_0000000000001249 crossref_primary_10_1002_ijc_31106 crossref_primary_10_7759_cureus_10696 crossref_primary_10_3389_fonc_2021_632231 crossref_primary_10_3390_cancers13164068 crossref_primary_10_1002_gcc_23198 crossref_primary_10_1080_10428194_2021_1929964 crossref_primary_10_1111_ijlh_13698 crossref_primary_10_1111_bjh_19142 crossref_primary_10_1111_ejh_13948 crossref_primary_10_1007_s00277_020_03953_3 crossref_primary_10_1186_s12887_023_03856_y crossref_primary_10_1016_j_leukres_2018_07_006 crossref_primary_10_1186_s12885_020_07781_6 crossref_primary_10_3390_genes12050687 crossref_primary_10_1016_j_clml_2024_08_005 crossref_primary_10_1016_j_ejphar_2019_172641 crossref_primary_10_24287_1726_1708_2019_18_1_112_126 crossref_primary_10_1016_j_humpath_2023_03_018 crossref_primary_10_1182_bloodadvances_2022007597 crossref_primary_10_1016_j_clml_2019_08_003 crossref_primary_10_1055_s_0043_1766133 crossref_primary_10_1016_j_beha_2018_09_003 crossref_primary_10_1016_j_pathol_2024_08_001 crossref_primary_10_1007_s11899_020_00597_y crossref_primary_10_1158_1078_0432_CCR_21_0553 crossref_primary_10_1016_j_yao_2021_02_014 crossref_primary_10_1111_bjh_17869 crossref_primary_10_1182_blood_2023023153 crossref_primary_10_3390_cells10061533 crossref_primary_10_3389_fonc_2023_1276695 crossref_primary_10_1016_j_exphem_2019_05_003 crossref_primary_10_1038_s41598_019_40786_1 crossref_primary_10_3390_ijms21062193 crossref_primary_10_1007_s12288_020_01295_8 crossref_primary_10_1038_s41598_021_85213_6 crossref_primary_10_1016_j_cll_2021_04_003 crossref_primary_10_1016_j_path_2023_01_001 crossref_primary_10_3390_jpm11080715 crossref_primary_10_1093_labmed_lmz008 crossref_primary_10_1016_S2152_2650_23_00307_5 crossref_primary_10_1016_j_clml_2025_05_013 crossref_primary_10_1016_j_jmoldx_2023_09_007 crossref_primary_10_1038_s41375_018_0144_7 crossref_primary_10_1016_j_mjafi_2023_11_011 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1182/blood-2016-12-758979 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine Chemistry Biology Anatomy & Physiology |
| EISSN | 1528-0020 |
| ExternalDocumentID | 28408464 |
| Genre | Clinical Trial Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: P30 CA016058 – fundername: NCI NIH HHS grantid: P30 CA021765 – fundername: NCI NIH HHS grantid: U10 CA180899 – fundername: NIGMS NIH HHS grantid: P50 GM115279 – fundername: NCI NIH HHS grantid: U10 CA180886 |
| GroupedDBID | --- -~X .55 0R~ 23N 2WC 34G 39C 4.4 53G 5GY 5RE 5VS 6J9 AAEDW AALRI AAXUO ABOCM ACGFO ADBBV ADVLN AENEX AFETI AFOSN AITUG AKRWK ALMA_UNASSIGNED_HOLDINGS AMRAJ BAWUL BTFSW CGR CS3 CUY CVF DIK DU5 E3Z EBS ECM EIF EJD EX3 F5P FDB FRP GS5 GX1 H13 IH2 K-O KQ8 L7B LSO MJL N9A NPM OK1 P2P R.V RHF RHI ROL SJN THE TR2 TWZ W2D W8F WH7 WOQ WOW X7M YHG YKV 7X8 ACVFH ADCNI AEUPX AFPUW AIGII AKBMS AKYEP EFKBS |
| ID | FETCH-LOGICAL-c529t-93e37421797d92bbc881856108280fb7353a3b803b04fb1ac6c7c9a8ab3b18192 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 230 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000403895200015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1528-0020 |
| IngestDate | Sun Sep 28 12:26:17 EDT 2025 Wed Feb 19 02:30:37 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 25 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c529t-93e37421797d92bbc881856108280fb7353a3b803b04fb1ac6c7c9a8ab3b18192 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
| ORCID | 0000-0002-4904-9767 |
| OpenAccessLink | https://dx.doi.org/10.1182/blood-2016-12-758979 |
| PMID | 28408464 |
| PQID | 1888677445 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1888677445 pubmed_primary_28408464 |
| PublicationCentury | 2000 |
| PublicationDate | 2017-06-22 20170622 |
| PublicationDateYYYYMMDD | 2017-06-22 |
| PublicationDate_xml | – month: 06 year: 2017 text: 2017-06-22 day: 22 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Blood |
| PublicationTitleAlternate | Blood |
| PublicationYear | 2017 |
| References | 28642359 - Blood. 2017 Jun 22;129(25):3280-3282 |
| References_xml | – reference: 28642359 - Blood. 2017 Jun 22;129(25):3280-3282 |
| SSID | ssj0014325 |
| Score | 2.6303885 |
| Snippet | Philadelphia chromosome-like (Ph-like) acute lymphoblastic leukemia (ALL) is a high-risk subtype characterized by genomic alterations that activate cytokine... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 3352 |
| SubjectTerms | Child Female Fusion Proteins, bcr-abl - genetics Gene Expression Regulation, Leukemic Gene Fusion Humans Interleukin-7 Receptor alpha Subunit - genetics Janus Kinase 2 - genetics Male Mutation Philadelphia Chromosome Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - genetics Protein Kinases - genetics Receptors, Cytokine - genetics Retrospective Studies Transcriptome |
| Title | Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/28408464 https://www.proquest.com/docview/1888677445 |
| Volume | 129 |
| WOSCitedRecordID | wos000403895200015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JS8NAFH6odbu41H3jCaKnwSSTZBIv0haLh7Z6UOhFysxkAkVM1ajQf--bSYo3EbyEXALJ5M1831s_gDMyAjIcHTJPmIyFuQ6YDKOMmVD7OsoD46eV2IQYDJLhML2vA25lXVY5OxPdQZ1NtI2RX_rkqsXEVcLo-vWNWdUom12tJTTmocGJylirFsOfLELInegqQVTCLC-qW-eIUl9WZeGEfk6FhkhzKn4hmQ5suuv_fc0NWKtpJrYqu9iEOVM0YatVkIv9MsVzdIWfLqLehKX27G6lM5N_a8Jyv866b8HTgysXt01W-DwuCPeQzM5g_mlDbSWOC7RTj5ktU8c2a_V6VyjRDa5F276CRDKxU3eNX5R4V7hR2VN0ga9teOzePHRuWS3LwHQUpB8s5YaTQ007WWRpoJROLOgTDSPnzcuV4BGXXCUeV16YK1_qWAudykQqrnw7f20HFopJYfYAbSNrLDztC54Tk8hTqaWMo0ArXwliTvtwOlvlEX2-zWXIwkw-y9HPOu_DbvWrRq_VfI4RIa5HtCo8-MPTh7AaWKD2YhYER9DIadObY1jUXx_j8v3E2RNdB_f9b0go0hM |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Targetable+kinase+gene+fusions+in+high-risk+B-ALL%3A+a+study+from+the+Children%27s+Oncology+Group&rft.jtitle=Blood&rft.au=Reshmi%2C+Shalini+C&rft.au=Harvey%2C+Richard+C&rft.au=Roberts%2C+Kathryn+G&rft.au=Stonerock%2C+Eileen&rft.date=2017-06-22&rft.eissn=1528-0020&rft.volume=129&rft.issue=25&rft.spage=3352&rft_id=info:doi/10.1182%2Fblood-2016-12-758979&rft_id=info%3Apmid%2F28408464&rft_id=info%3Apmid%2F28408464&rft.externalDocID=28408464 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1528-0020&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1528-0020&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1528-0020&client=summon |